BioSig Expands its Installation Base in Texas
Signs a new installation agreement with high-volume center in San Antonio Westport, CT – November 04, 2021 – BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced […]
BioSig Technologies, Inc. Appoints Medical Device Industry Leader to its Board of Directors
James J. Barry, Ph.D. will join as an Independent Director as Company expands clinical footprint with its signal processing technology for arrhythmia care Westport, CT – September 21, 2021 — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity […]
BioSig Completes 1000 Patient Cases with its Signal Processing System for Electrophysiology
The Company recently increased its procedural volume targets due to accelerated technology usage BioSig expands its commercial team to target technology adoption across three strategic regions Westport, CT – June 30, 2021 — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform […]
Major Medical Centers Enter into Installation Agreements for Evaluation of BioSig PURE EP™ Systems
New 90-day evaluation cycles enable hospitals to more rapidly assess the platform technology while also accelerating BioSig’s commercial activities Westport, CT – February 11, 2021 – BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full […]
BioSig and Mayo Clinic Collaborate on New R&D Program to Develop Transformative AI and Machine Learning Technologies for its PURE EP™ System
Global market for AI in healthcare is estimated to reach $45.2 billion by 2026 Westport, CT – February 2, 2021 — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac […]
ViralClear adds St. David’s HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19
Randomized, double-blind, placebo-controlled Phase II trial of merimepodib to be conducted in adults with COVID-19 who are hospitalized and require supplemental oxygen or are on non-invasive ventilation or high-flow oxygen devices Westport, CT – June 5, 2020 — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, […]
ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19 Novel Coronavirus in F1000 Research
Merimepodib is shown to decrease viral production of COVID-19 coronavirus more than remdesivir at clinically meaningful drug concentrations in pre-clinical testing. Article highlights recent work done in laboratory studies of COVID-19 with merimepodib at the Galveston National Laboratory at The University of Texas Medical Branch Westport, CT – April 23, 2020 – […]
Positive Data Generated by Biosig Subsidiary ViralClear on Covid-19 Coronavirus Published in bioRxiv
>> Vicromax shown to decrease viral production of Covid -19 coronavirus by over 98% >> Article highlights recent work done in laboratory studies of Covid -19 with Vicromax(tm) at the Galveston Lational Laboratory at The University of Texas Medical Branch Westport, CT – April 14, 2020 – BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or […]
BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19
>> Introduction to ViralClear management and scientific team >> Strategy for rapid FDA advancement of Vicromax(tm) >> Update on BioSig core business developments and commercialization plans Westport, CT, April 03, 2020 – BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform, today announced […]
Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc.
Former Chief Medical Officer of Celgene to lead development of Vicromax(tm), a novel broad-spectrum anti-viral agent that may treat COVID-19 Westport, CT – March 31, 2020 – BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform, today announced that it appointed Jerome Zeldis, […]
